# Melanotan II Reviews — The Peer-Reviewed Record, Xeroxed and Stapled > An editorial reading of the Melanotan II research literature: mechanism, University of Arizona history, clinical trials, case reports, and the harm-reduction information that social media left out. not a buyer's guide. a reading of what is and is not in the record. ## What you're actually looking at Melanotan II is a synthetic peptide built at the University of Arizona in the early 1990s. It mimics the body's own melanin-stimulating hormone — but it's stronger, lasts longer, and hits four different receptors at once, which is why it does more than just darken skin. The research record covers tanning, erections, appetite suppression, and a growing stack of case reports documenting serious adverse events in people who self-administered it. None of that came from large clinical trials. The controlled human database is 23 subjects across three small studies, all run before 2001. This site reads that record straight, without the marketing gloss and without pretending it's more complete than it is. The [effects page](/effects) covers what people report and what the research cautions. ## Where It Came From Melanotan II did not originate in a supplement catalog. It came out of the University of Arizona's Department of Biochemistry and Pharmacology in the early 1990s, where Mac Hadley, Victor Hruby, Robert Dorr, and Norman Levine were trying to solve a different problem: they wanted a metabolically stable analog of alpha-melanocyte-stimulating hormone (α-MSH) that could stimulate skin pigmentation and potentially reduce UV-induced skin cancer risk [1]. The parent molecule, native α-MSH, is a 13-amino-acid peptide that the body produces naturally but degrades in plasma within about one to two minutes — too fast to be clinically useful. The Arizona team built a cyclic heptapeptide, seven amino acids arranged in a ring stabilized by a lactam bridge between positions two and seven, with norleucine and D-phenylalanine substitutions to improve metabolic resistance. The result was approximately 1,000 times more potent than α-MSH in melanotropic bioassays and carried a plasma half-life of approximately one hour post-injection [1]. The first human pilot study ran in 1996: three healthy male volunteers, subcutaneous injections at escalating doses of 0.01–0.025 mg/kg over two weeks. Two of three subjects showed measurable pigmentation increases. One subject, unexpectedly, reported spontaneous penile erections lasting one to five hours post-injection [1]. That single observation redirected part of the research program entirely. Within two years the same team was running double-blind, placebo-controlled crossover trials in men with erectile dysfunction, and the data from those trials eventually traveled the licensing path from the University of Arizona through Competitive Technologies to Palatin Technologies, where the derived compound bremelanotide received FDA approval in 2019 [2][3]. MT-II itself was never approved for any indication. The compound that cleared the FDA was bremelanotide — structurally a near-twin, differing from MT-II only at the C-terminus, where the amide group was changed to a free acid, which reduced MC1R (pigmentation) activity while preserving MC4R (sexual function) agonism. MT-II remains unapproved. The peer-reviewed record of its research is the subject of this site. ## How the Molecule Works Melanotan II is a nonselective melanocortin receptor agonist. It binds MC1R, MC3R, MC4R, and MC5R — but not the adrenocorticotropin-specific MC2R. That nonselective binding profile is the central pharmacological fact about MT-II: you cannot get the pigmentation effect without also hitting the receptors that drive appetite suppression, thermogenesis, and pro-erectile signaling at standard research doses. At MC1R, the mechanism is comparatively well-characterized. MT-II binding activates adenylyl cyclase, raising intracellular cyclic AMP, which activates protein kinase A, which upregulates MITF and downstream tyrosinase activity. Tyrosinase is the rate-limiting enzyme in melanin synthesis. Critically, MT-II shifts synthesis preferentially toward eumelanin — the brown-to-black pigment form — rather than pheomelanin, which produces red-yellow tones. Pigmentation can occur in the absence of UV exposure, though existing evidence suggests UV exposure amplifies the melanogenic response [12]. At MC4R, the story is more complicated. Hypothalamic and limbic MC4R activation drives a cluster of effects: appetite suppression, thermogenesis through brown adipose tissue, and pro-erectile signaling via central sympathomimetic pathways [4][5][6]. In rodent models, the appetite-suppression finding is robust. Bilateral microinjection of MT-II into the nucleus accumbens of male mice at 0.3 nmol per side produced dose-dependent suppression of both appetitive and consumptive food-seeking behavior, with suppression of intake persisting for 24 hours at the higher dose [4]. Separate rat infusion studies showed MT-II could cancel NPY-driven hyperphagia and substantially reduce NPY-induced fat pad weight gain at 15 nmol/day ICV infusion [6]. The nonselective binding profile is also why the gap between MT-II and bremelanotide matters clinically. Researchers specifically modified the C-terminus of MT-II to reduce MC1R selectivity and increase MC4R specificity before pursuing FDA approval for a sexual dysfunction indication. The approved compound does not cause the same degree of pigmentation. MT-II does both simultaneously, with no mechanism available to separate them at research doses documented so far. ## What the Clinical Record Shows The clinical record for Melanotan II is small and old. Three controlled human studies exist: the 1996 Dorr et al. phase I tanning pilot (n=3), and the two Wessells et al. erectile dysfunction crossover trials from 1998 and 2000 (n=10 each) [1][2][3]. No large randomized controlled trials have been conducted. No NDA was ever filed for MT-II. Clinical development was redirected to bremelanotide before the program reached phase III. The Wessells 1998 study [2] produced the clearest efficacy signal: in a double-blind, placebo-controlled crossover design in ten men with psychogenic erectile dysfunction, MT-II at 0.025 mg/kg subcutaneous produced clinically apparent erections by RigiScan in 8 of 10 subjects. Mean duration of tip rigidity greater than 80% was 38.0 minutes versus 3.0 minutes with placebo (p=0.0045). The Wessells 2000 study [3] extended this finding to men with organic erectile dysfunction — a harder population — and found 12 of 19 MT-II injections produced subjective erections versus 1 of 21 placebo doses. Nausea was the most common adverse event in both studies. For perspective on scale: the two ED trials together enrolled 20 subjects. The 1996 tanning pilot enrolled 3. The total number of subjects in controlled human MT-II trials is 23. The remainder of the human literature consists of case reports — which, in this compound's case, are substantial and document serious adverse events. That literature is covered in the research section of this site. Recent years have added a different kind of human data: qualitative sociology. Two 2024 studies and one 2025 JAAD study document user experiences through interview and survey methods, characterizing demographics, motivations, harm communication patterns, and the gap between how users perceive MT-II risk and what the case-report literature actually documents [16][19][21]. ## What This Site Is This is not a buyer's guide. It is not affiliated with any vendor, supplier, or retailer. It does not sell anything. It does not recommend anything. Melanotan II Reviews is an independent editorial publisher that summarizes the peer-reviewed research literature on Melanotan II. Every claim on this site cites a primary source. Every quantitative finding attributes a specific study. The editorial position is that the research deserves to be read — both the controlled trials that produced measurable results, and the case reports that document what happens when the compound is used without clinical oversight at uncontrolled doses. The site is organized across seven pages: an index (this page), a research summary covering mechanism and clinical findings, a dosage research context page, a FAQ, a complete references index, an about page, and a contact page. Navigation is above. --- An independent editorial reading of the peer-reviewed record — not a clinic, not a vendor, not a dosing guide.